Cardiovascular Effects of Switching From Tobacco Cigarettes to Electronic Cigarettes by George, Jacob et al.
Listen to this manuscript’s
audio summary by
Editor-in-Chief
Dr. Valentin Fuster on
JACC.org.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 7 4 , N O . 2 5 , 2 0 1 9
ª 2 0 1 9 T H E A U T H O R S . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E AM E R I C A N
C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R
T H E C C B Y L I C E N S E ( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y / 4 . 0 / ) .Cardiovascular Effects of Switching
From Tobacco Cigarettes to
Electronic Cigarettes
Jacob George, MD,a Muhammad Hussain, MSC,a Thenmalar Vadiveloo, PHD,b Sheila Ireland, BSC,a
Pippa Hopkinson, BSC,a Allan D. Struthers, MD,a Peter T. Donnan, PHD,b Faisel Khan, PHD,c,* Chim C. Lang, MDa,*ABSTRACTISS
Fro
Un
Du
Du
(Va
15/
Ce
da
fro
of
MaBACKGROUND E-cigarette (EC) use is increasing exponentially worldwide. The early cardiovascular effects of
switching from tobacco cigarettes (TC) to EC in chronic smokers is unknown. Meta-analysis of ﬂow-mediated dilation
(FMD) studies indicate 13% lower pooled, adjusted relative risks of cardiovascular events with every 1% improvement
in FMD.
OBJECTIVES This study sought to determine the early vascular impact of switching from TC to EC in chronic smokers.
METHODS The authors conducted a prospective, randomized control trial with a parallel nonrandomized preference
cohort and blinded endpoint of smokers$18 years of age who had smoked$15 cigarettes/day for$2 years and were free
from established cardiovascular disease. Participants were randomized to EC with nicotine or EC without nicotine for
1 month. Those unwilling to quit continued with TC in a parallel preference arm. A propensity score analysis was done to
adjust for differences between the randomized and preference arms. Vascular function was assessed by FMD and pulse
wave velocity. Compliance with EC was measured by carbon monoxide levels.
RESULTS Within 1 month of switching from TC to EC, there was a signiﬁcant improvement in endothelial function (linear
trend b ¼ 0.73%; 95% conﬁdence interval [CI]: 0.41 to 1.05; p < 0.0001; TC vs. EC combined: 1.49%; 95% CI: 0.93 to
2.04; p < 0.0001) and vascular stiffness (0.529 m/s; 95% CI: 0.946 to 0.112; p ¼ 0.014). Females beneﬁted from
switching more than males did in every between-group comparison. Those who complied best with EC switch demon-
strated the largest improvement. There was no difference in vascular effects between EC with and without nicotine
within the study timeframe.
CONCLUSIONS TC smokers, particularly females, demonstrate signiﬁcant improvement in vascular health
within 1 month of switching from TC to EC. Switching from TC to EC may be considered a harms reduction measure.
(Vascular Effects of Regular Cigarettes Versus Electronic Cigarette Use [VESUVIUS]; NCT02878421;
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AB BR E V I A T I O N S
AND ACRONYM S
CI = conﬁdence interval
CO = carbon monoxide
CV = cardiovascular
EC = electronic cigarette
FMD = ﬂow-mediated dilation
OR = odds ratio
PWV = pulse wave velocity
TC = tobacco cigarette
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3113E lectronic cigarettes or E-cigarettes (EC) aregaining popularity worldwide as an alterna-tive to smoking tobacco cigarettes (TC) with
a 55% increase in users between 2013 and 2015 with
growth in the United Kingdom occurring fastest in
Europe (1). The prevalence of EC use in the United
Kingdom and United States is around 6% (2), and
51% of users did so because they believed it to be
less harmful than regular cigarettes (3). Observational
data in the 2014 and 2016 U.S. National Health Inter-
view Surveys revealed that although the risk of
myocardial infarction remains higher with TC (odds
ratio [OR]: 2.72; 95% conﬁdence interval [CI]: 2.29 to
3.24), daily EC use was also associated with an
increased myocardial infarction risk (OR: 1.79;
95% CI: 1.20 to 2.66) (4). Despite this, there remains
little good quality evidence on the short- and long-
term safety of these devices. Furthermore, conﬂicting
advice from various public health bodies worldwide on
the use of these devices has resulted in lack of clarity
for policymakers as well as the public at large (5,6).SEE PAGE 3121TC contain >7,000 chemicals, including exposing
smokers to high levels of nicotine, carbon monoxide
(CO), acrolein, and pro-oxidant compounds. Data
from chemical analysis and toxicology studies sug-
gest that exposure to toxic chemicals from EC is lower
compared with exposure from TC (7,8). However,
other studies have shown that there remains the
presence of potentially harmful tobacco-speciﬁc al-
kaloids such as anabasine, myosmine, and b-nic-
otyrine in EC liquid cartridge samples tested (9). The
impact of nicotine on vascular health is also unclear.
Nicotine may accelerate the atherogenic process by
binding to high-afﬁnity nicotinic acetylcholine
receptor cell surface receptors (10). However, longer-
term nicotine use appears not to accelerate athero-
genesis but may contribute to acute cardiovascular
events in the presence of cardiovascular (CV) disease
(11). The early vascular impact of switching from TC to
EC–nicotine versus EC- nicotine-free is not known.
Endothelial dysfunction is the earliest detectable
change in vascular health, and, importantly, it has
consistently been shown to be associated with CV risk
and long-term outcomes (12,13). We measured endo-
thelial function using ﬂow-mediated dilatation (FMD)
and arterial stiffness by pulse wave velocity (PWV), 2
validated and independent predictors of CV risk
above and beyond traditional risk factors (14,15). We
conducted the current trial to address speciﬁc ques-
tions on the early CV effects of switching from TC to
EC and the impact of nicotine itself on any early
vascular changes that might be seen.METHODS
The VESUVIUS (Vascular Effects of Regular
Cigarettes Versus Electronic Cigarette Use)
trial (NCT02878421) was a prospective, ran-
domized controlled trial with a parallel,
nonrandomized preference cohort and blin-
ded endpoint of smokers $18 years of age
who had smoked $15 cigarettes/day for at
least 2 years; were free from established CV
disease, diabetes, and chronic kidney dis-
ease; and were not on medication for those
conditions. The trial was conducted between August
2016 and July 2018 in a single tertiary research center.
Participants were recruited from local advertise-
ments, smoking cessation databases, and visits to
local businesses, as well as via the Scottish Primary
Care Research Network. Consented participants who
were willing to quit smoking were randomized to one
of the EC arms in a 1:1 fashion using a centrally
controlled web-based good clinical practices–
compliant randomization system (TrusT, Health
Informatics Centre, University of Dundee) to either:
1) EC containing 16 mg nicotine (Vapourlites Starter
Kit with XR5 16 mg nicotine cartomizer; Vapourlites,
Peterlee, United Kingdom); or 2) nicotine-free EC plus
nicotine ﬂavoring (Vapourlites Starter Kit with 0 mg
nicotine cartomizer) because it was considered by the
institutional ethics committee as ethically unaccept-
able to randomize those who were willing to quit
smoking into a smoking arm. Those unwilling to
consider quitting smoking continued in the parallel
preference TC cohort. Participants in the TC arm
continued their usual daily smoking habits and did
not use EC for the 4-week period of the trial. The
study was approved by the Tayside Research Ethics
Committee and was carried out in accordance with
the Declaration of Helsinki. Exhaled CO breath test
was measured as an indicator of treatment allocation
adherence to EC, as in previous trials (16), and was
added to the primary model to assess the effect of
adherence. Studies have previously shown that CO
levels fall signiﬁcantly when switching completely
from TC to EC (17).
The primary efﬁcacy endpoint was change in FMD
among the TC group and the EC-nicotine and EC-
nicotine-free groups.
FLOW-MEDIATED DILATION. Endothelial function
was assessed by measuring FMD of the brachial artery
using a Sequoia 512 (Siemens, Camberley, United
Kingdom) and an 8-MHz linear array ultrasound
probe as described previously (18). Patients fasted
overnight and measurements were conducted at
baseline and 1 month according to the International
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3114Brachial Artery Reactivity Task Force guidelines (19)
by a single operator (M.H.) blinded to study allocation
at a single site. All participants were required to
refrain from smoking TC or EC for 4 h before each
FMD test.
PULSE WAVE VELOCITY. Pulse wave velocity and
augmentation index were measured at baseline and
1 month by a single operator (M.H.) blinded to study
allocation. Measurements were recorded with a
SphygmoCor (AtCor, Sydney, Australia) machine us-
ing a high-ﬁdelity micromanometer.
BIOMARKERS. We measured oxidized low-density
lipoprotein, high-sensitivity C-reactive protein, tis-
sue plasminogen activator, and platelet activation
inhibitor-1 at baseline and at 1 month. All biomarkers
were measured by enzyme-linked immunosorbent
assay at the Immunoassay Biomarker Core Labora-
tory, University of Dundee.
OUTCOMES. The primary outcome was deﬁned as the
change in FMD among the TC group and the EC-
nicotine and EC-nicotine-free arms as a linear
contrast. Secondary outcomes included change in
FMD, PWV, augmentation index at 75 beats/min,
heart rate, blood pressure, and biomarkers (oxidized
low-density lipoprotein, high-sensitivity C-reactive
protein, tissue plasminogen activator, and platelet
activation inhibitor-1) for the TC, EC-nicotine, and
EC-nicotine-free arms.
STATISTICAL ANALYSIS. The primary endpoint of
change in brachial artery FMD is expressed as the
maximum FMD percentage change from baseline.
Using linear contrast tests, a sample size of 36 sub-
jects in each group would have 80% power to detect
an improvement in FMD of 2.0% and 1.0% in the EC-
nicotine-free and EC-nicotine arms, respectively,
compared with the TC group at 5% signiﬁcance. In
this explanatory trial, all dropouts were replaced to
achieve 36 completed subjects in each group. The pri-
mary analysis was performed on a per-protocol basis.
Descriptive statistics in the form of mean  SD for
continuous variables and percentages and de-
nominators for categorical variables are tabulated for
baseline and at the 1-month visit. The dependent
variable was assessed for approximation to a
normal distribution and transformed if necessary.
The FMD response relationship was assessed by a
linear contrast test (TC, EC-nicotine, EC-nicotine-
free) in a multiple linear regression on FMD at
4 weeks including the baseline FMD level and
experimental group as covariates. The model
also included the minimization variables: baseline
age (#40 years, >40 years); sex (male, female);
and smoking pack-years (#20 pack-years,>20 pack-years). Pre-speciﬁed subgroup analyses
were completed by ﬁtting the appropriate interaction
term in the regression model and, if signiﬁcant, out-
comes were analyzed separately by level of subgroup.
All comparisons were performed among treatment
arms (TC vs. EC-nicotine vs. EC-nicotine-free) at the
ﬁnal visit (4 weeks) and adjusted for the baseline
measure of the outcome.
As the parallel control arm expressed a preference
to not be randomized, a propensity score was created
with the binary outcome of randomized versus non-
randomized using logistic regression and subse-
quently used as an adjustment covariate in the
regression models to allow for potential bias. Vari-
ables included in the propensity score included de-
mographic data, blood pressure, CO levels, all
measured biomarkers, FMD and vascular stiffness
parameters, and smoking history (Online Table 1).
All analyses were conducted in SAS version 9.4
(SAS Institute Inc., Cary, North Carolina).
RESULTS
A total of 145 patients were recruited into the trial
(Figure 1). A ﬁnal number of 114 patients (40 TC, 37
EC-nicotine, 37 EC-nicotine-free) completed both
visits. Baseline demographic data and smoking his-
tory among the 3 arms were comparable and are
shown in Table 1. There were no serious adverse
events reported during the trial.
PRIMARY OUTCOME. The primary outcome of
change in FMD of the brachial artery showed a sig-
niﬁcant trend in the difference among arms from TC
to EC-nicotine to EC-nicotine-free (linear trend b for
TC, EC-nicotine, EC-nicotine-free ¼ 0.73%; 95% CI:
0.41 to 1.05; p < 0.0001). Within 1 month of switching
from TC to EC, FMD signiﬁcantly improved among TC
and combined EC arms (1.49%; 95% CI: 0.93 to 2.04;
p < 0.0001) and separately between TC and EC-
nicotine and between TC and EC-nicotine-free
(Table 2). There was no statistically signiﬁcant dif-
ference in FMD change between the EC-nicotine and
EC-nicotine-free arms (Table 2, Central Illustration).
The interaction term between treatment and sex
for the primary outcome of FMD change was statisti-
cally signiﬁcant (p ¼ 0.009), therefore the subgroup
analyses was performed by sex. The improvement in
FMD was seen in both males and females for TC
versus EC comparisons but signiﬁcantly greater
improvement in vascular function was seen in fe-
males who switched from TC to EC (Table 3).
As expected, exhaled CO levels were high at base-
line and comparable among the 3 arms of the study
(Table 1). However, at the end of study, those with the
FIGURE 1 CONSORT Diagram
Ineligible due to inclusion/exclusion
criteria (n = 238)
Lost to follow-up (n = 29)
New statin prescription (n = 1)
FMD data unsuitable for
analysis (n = 1)
E-cigarette (EC) –
Nicotine
n = 37
E-cigarette (EC) +
Nicotine
n = 37
Tobacco cigarettes
(TC)
n = 40
Total screened (n = 383)
Baseline visit 1
(n = 145)
Visit 2 (n = 115)
Final evaluable dataset
(n = 114)
Flow chart showing patient involvement in the study. CONSORT ¼ Consolidated Standards of Reporting Trials; EC ¼ electronic cigarettes; FMD ¼ ﬂow-
mediated dilation; TC ¼ tobacco cigarettes.
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3115lowest tertile of CO (best compliance with EC and
least dual use) had the greatest gain in vascular
function improvement. In the lowest tertile of CO,
once again, females who switched from TC to EC had
a much greater gain in vascular function improve-
ment than did males. Females who complied less well
with allocated therapy (dual use with TC) at the
middle and high CO tertiles, still beneﬁted from
switching to EC more than males did (Table 4). Data
on noncompliant subjects are shown in Online
Table 2.
Data from our lab for age- and sex-matched
nonsmoking healthy volunteers indicate a mean
FMD of 7.7%. To put this into context, over a 4-week
switch, chronic smokers who switched from TC to
EC-nicotine showed improved mean FMD from 5.5%
to 6.7% and those who switched from TC toEC-nicotine-free showed improved mean FMD from
5.3% to 6.6%.
SECONDARY OUTCOMES. There was no signiﬁcant
trend in difference among the 3 arms for other sec-
ondary outcomes including PWV, heart rate, and
biomarkers of inﬂammation and platelet reactivity
(Table 5). However, the interaction terms between
treatment and smoking pack-years were signiﬁcant
for PWV (p ¼ 0.016) and heart rate (p ¼ 0.003).
Therefore, a subgroup analysis was done for these
outcomes by smoking pack-years.
VASCULAR STIFFNESS AND BLOOD PRESSURE.
Smokers who smoked #20 pack-years also demon-
strated an improvement in vascular stiffness within
1 month of switching from TC to EC with an
improvement in PWV (0.471 m/s; 95% CI: 0.834
to 0.107; p ¼ 0.014), whereas those who smoked
TABLE 1 Demography of the Evaluable Dataset by Study Arm
TC
(n ¼ 40, 35.0%)
EC-Nicotine
(n ¼ 37, 32.5%)
EC-Nicotine-Free
(n ¼ 37, 32.5%)
Male 13 (32.5) 14 (37.8) 12 (33.4)
Age, yrs 44.2 (40.4–47.9) 48.0 (44.7–51.3) 48.4 (43.5–53.3)
Weekly alcohol intake, U 0.0 [0.0–11.0] 0.0 [0.0–10.0] 4.0 [0.0–12.0]
BMI 26.7 (25.0–28.5) 28.1 (25.8–30.4) 27.1 (25.4–28.8)
Employment status
FT 23 (57.5) 14 (37.8) 16 (43.2)
PT 3 (7.5) 5 (13.5) 7 (18.9)
Unemployed 7 (17.5) 10 (27.0) 7 (18.9)
Other 7 (17.5) 8 (21.6) 7 (18.9)
CO, ppm 12.0 [7.3–20.8] 12.0 [7.5–16.0] 11.0 [7.0–14.0]
CO% COHb 2.6 [1.8–4.0] 2.6 [1.9–3.2] 2.4 [1.8–2.9]
Age started smoking, yrs 15.0 [13.0–16.5] 14.0 [13.0–16.0] 16.0 [13.0–18.0]
Cigarettes per day 20 [15–20] 18 [15–20] 18 [15–20]
Years smoked 29.0 [19.5–36.5] 36.0 [25.0–41.0] 32.0 [22.0–40.0]
Pack-year history 25.4 [15.5–36.5] 33.3 [21.8–44.0] 27 [19.9–36.8]
Parents smoked
No 8 (20.0) 6 (16.2) 10 (27.0)
Yes 32 (80.0) 31 (83.8) 27 (73.0)
Other smokers in the home
0 23 (57.5) 24 (64.9) 29 (78.4)
1 15 (37.5) 13 (35.1) 8 (21.6)
2 2 (5.0) 0 (0.0) 0 (0.0)
Values are n (%), mean (95% conﬁdence interval), or median [interquartile range]. Analysis of variance used for
age, height, weight, BMI, systolic BP, diastolic BP and heart rate. Chi-square test used for categorical variables,
sex, and employment status. Kruskal-Wallis test used for age started smoking, cigarettes per day, years smoked,
pack-year history weekly alcohol intake, CO ppm, and CO% COHb.
BMI ¼ body mass index; BP ¼ blood pressure; CO ¼ carbon monoxide; CO% COHb ¼ percentage of CO in
carboxyhemoglobin; EC ¼ electronic cigarettes; FT ¼ full time; ppm ¼ parts per million; PT ¼ part time;
TC ¼ total cigarettes.
TABLE 2 Regression
Less Nicotine
Primary outcome*
Change in FMD (þ1 g
3 ¼ EC-nicotine-fre
Secondary outcomes*
Change in FMD, EC-n
Change in FMD, EC-n
Change in FMD, all E
Change in FMD, EC-n
Values are regression coef
>40 years), sex (male, fem
CI ¼ conﬁdence interval
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frame (Table 5). For the whole cohort, when both EC
arms were combined, there was a signiﬁcant
improvement in PWV in this combined EC group
compared with in the TC group (0.529 m/s;
95% CI: 0.946 to 0.112; p ¼ 0.014). When both EC
groups were combined, there was a greater reductionAnalysis of Outcomes for FMD—Linear Contrast With Higher Arm
Difference Between
Arms in Change p Value
roup, 1 ¼ TC, 2 ¼ EC-nicotine,
e)
0.73 (0.41 to 1.05) <0.0001
icotine-free vs. TC (ref) 1.52 (0.90 to 2.15) <0.0001
icotine vs. TC (ref) 1.44 (0.78 to 2.09) <0.0001
C vs. TC (ref) 1.49 (0.93 to 2.04) <0.0001
icotine-free vs. EC-nicotine (ref) 0.09 (0.52 to 0.69) 0.78
ﬁcient (95% CI). *Adjusted for baseline of the outcome, baseline age (#40 years,
ale), and smoking pack-years (#20 pack-years, >20 pack-years).
; FMD ¼ ﬂow-mediated dilatation; ref ¼ reference; other abbreviations as in Table 1.in systolic blood pressure in the EC group than in the
TC group, both in smokers of #20 pack-years
(EC: 4.41 mm Hg; 95% CI: 7.91 to 0.91 vs.
TC: 2.86 mm Hg; 95% CI: 8.09 to 2.38; p ¼ 0.59)
and >20 pack-years (EC: 7.75 mm Hg; 95% CI: 11.56
to 3.93 vs. TC: 1.37 mm Hg; 95% CI: 5.32 to
2.59; p ¼ 0.04).
Using analysis of variance, there was a signiﬁcant
difference for the mean change of systolic blood
pressure among the 3 arms: TC (1.89 mm Hg;
95% CI: 4.91 to 1.14); EC-nicotine (4.27 mm Hg;
95% CI: 7.73 to 0.81); EC-nicotine-free
(9.69 mm Hg; 95% CI: 14.67 to 4.71), p ¼ 0.01.
When adjusted for baseline variables, the trend
remained toward lower systolic blood pressures
among arms from TC to EC-nicotine to EC-nicotine-
free but was not statistically signiﬁcant
(b ¼ 2.2 mm Hg; 95% CI: 4.8 to 0.5; p ¼ 0.11). The
greatest difference in systolic blood pressure was
seen in the TC versus EC-nicotine-free arms
(4.3 mm Hg; 95% CI: –9.6 to 1.0; p ¼ 0.11) followed
by TC versus EC-nicotine arms (2.0 mm Hg; 95% CI:
–7.6 to 3.5; p ¼ 0.47).
HEART RATE. For smokers who smoked #20 pack-
years (n ¼ 31), resting heart rate signiﬁcantly
increased by 2.6 beats/min (95% CI: 0.3 to 5.0) for
EC-nicotine compared with the rate for TC and
increased by 5.2 beats/min (95% CI: 0.6 to 10.0) for
EC-nicotine-free compared with the rate for TC
(p ¼ 0.03). However, for smokers who smoked
>20 pack-years (n ¼ 82), resting heart rate decreased
by 2.8 beats/min (95% CI: 5.2 to 0.4) for EC-
nicotine compared with the rate for TC and
decreased further by 5.6 beats/min (95% CI: 10.4
to 0.8) for EC-nicotine-free compared with the rate
for TC (p ¼ 0.02).
DISCUSSION
The main ﬁndings from this present study are that
within 1 month of switching from TC to EC, smokers
demonstrate a signiﬁcant improvement in vascular
function. The data from this present trial on the early
CV impact of switching from TC to EC has yielded
several clinically important ﬁndings.
First, there is an early beneﬁt to vascular function
from switching from TC to EC. Within the switching
time frame of 1 month, chronic smokers demon-
strated signiﬁcant improvements in vascular endo-
thelial function. This is consistent with the recent
review by Benowitz and Fraiman (20) that switching
from TC to EC might result in overall beneﬁt to public
health. Previous meta-analysis of FMD studies have
demonstrated that the pooled, adjusted relative risks
CENTRAL ILLUSTRATION Change in Mean Flow-Mediated Dilation Among Tobacco Cigarettes and
Electronic Cigarettes With and Without Nicotine
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Adjusted mean percentage change in forearm ﬂow-mediated dilation with 95% conﬁdence intervals for subjects on electronic cigarettes (EC), EC-nicotine, and EC-
nicotine-free.
TABLE 3 Regression Analysis of FMD Primary Outcomes by Sex Subgroup—Linear
Contrast With Higher Arm Less Nicotine
Difference Between
Arms in Change p Value
Change in FMD (þ1 group, 1 ¼ TC,
2 ¼ EC-nicotine, 3 ¼ EC-nicotine-free)
Male 0.213 (0.248 to 0.675) 0.351
Female 1.049 (0.617 to 1.480) <0.0001
Change in FMD, EC-nicotine-free vs. TC (ref)
Male 0.448 (0.451 to 1.347) 0.315
Female 2.183 (1.336 to 3.030) <0.0001
Change in FMD, EC-nicotine vs. TC (ref)
Male 0.822 (0.067 to 1.710) 0.069
Female 1.824 (0.942 to 2.706) <0.0001
Change in FMD, EC-nicotine-free vs.
EC-nicotine (ref)
Male 0.374 (1.239 to 0.492) 0.384
Female 0.359 (0.449 to 1.167) 0.377
Values are regression coefﬁcient (95% CI). Adjusted for baseline of the outcome, baseline age (#40 years,
>40 years) and smoking pack-years (#20 pack-years, >20 pack-years).
Abbreviations as in Tables 1 and 2.
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ment in FMD (12). As we have demonstrated with age-
and sex-matched healthy volunteer FMD data from
our lab, otherwise healthy but chronic TC smokers
who switched to EC improved their vascular function,
approaching values seen in healthy nonsmokers.
Within 1 month of switching from TC, we found a 1.5%
improvement between TC and EC-nicotine-free arms,
1.4% improvement between TC and EC-nicotine arms,
and a 1.5% improvement between TC and combined
EC arms (Table 2).
Second, vascular stiffness was also signiﬁcantly
reduced within 1 month of switching in smokers
of #20 pack-years compared with in those who
smoked >20 pack-years, suggesting that the trend
toward lower blood pressure in the EC arms could be
important. Longer term studies are required to detect
whether there are statistically and clinically signiﬁ-
cant reductions in blood pressure when switching
from TC to EC as a result of improvements in vascular
stiffness.
Third, switching to EC from TC may beneﬁt females
more than males and this is also seen in females who
were less compliant (dual use). However, this was a
subgroup analysis of our data and should be inter-
preted with caution. Nevertheless, female smokers
face more health risks than male smokers do; they are
more likely to develop lung cancer (21) and are almosttwice as likely to have a myocardial infarction as a
result of their smoking (22). The worrying trend
worldwide of increased TC prevalence among women
(23) suggests that further measures are urgently
required to reduce harms associated with TC.
Therefore, the switch to EC may be considered a
vascular harms reduction measure for both sexes but
TABLE 5 Regression
Arm Less Nicotine
Carotid femoral pulse w
#20 pack-years, n ¼
>20 pack-years, n ¼
Heart rate
#20 pack-years, n ¼
>20 pack-years, n ¼
Augmentation index,75
Oxidized LDL
High-sensitivity CRP*
Tissue plasminogen act
Platelet activation inhi
Systolic blood pressure
Diastolic blood pressur
Values are regression coefﬁ
age (#40 years, >40 year
*Log-transformed.
CI ¼ conﬁdence interval
TABLE 4 Change in FMD—Mean and 95% CI by CO Tertiles, Sex, and Group
CO Tertile Sex TC EC-Nicotine EC-Nicotine-Free
Low, 0–5 ppm Male 0.28* [1] 1.23 (0.02 to 2.44) [6] 0.79 (0.38 to 1.21) [6]
Female 0.29* [1] 1.58 (0.50 to 2.66) [12] 2.26 (1.31 to 3.21) [11]
Both 0.29 (0.22 to 0.35) 1.46 (0.71 to 2.22) 1.74 (1.05 to 2.43)
Middle, 6–11 ppm Male 0.17 (0.57 to 0.91) [6] 0.81 (5.39 to 7.00) [2] 0.23 (3.13 to 2.68) [3]
Female 0.64 (1.76 to 0.47) [9] 0.87 (0.02 to 1.72) [7] 1.43 (0.71 to 2.15) [10]
Both 0.32 (1.01 to 0.37) 0.86 (0.22 to 1.50) 1.05 (0.31 to 1.79)
High, 12–32 ppm Male 0.43 (0.40 to 1.25) [6] 0.83 (0.40 to 2.07) [6] 0.51 (3.81 to 4.83) [3]
Female 0.16 (0.30 to 0.62) [17] 1.74 (0.77 to 4.25) [4] 1.55 (0.59 to 2.52) [4]
Both 0.23 (0.14 to 0.60) 1.20 (0.23 to 2.16) 1.11 (0.03 to 2.24)
Values are mean (95% CI) [n]. *95 CI% not estimable.
Abbreviations as in Tables 1 and 2.
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who currently smoke TC (24).
Fourth, those who complied best with allocated
therapy, as indicated by exhaled CO levels, beneﬁtted
the most in terms of improvement in endothelial
function. Our data shows that those who avoided dual
use and had lowest CO levels derived greater vascular
beneﬁt from switching. Dual use of EC is a highly
prevalent reality worldwide (25). The beneﬁts of total
switching may have been even larger if subjects fully
complied with the switch. This ﬁnding could be used
to encourage smokers who dual use to minimize TC
exposure.
Finally, there was no difference observed between
the 2 EC arms (with and without nicotine) for this
short-term study. Early improvement appears to be
unrelated to the abstinence from nicotine but rather
from other toxic material produced by combustion inAnalysis of Secondary Outcomes—Linear Contrast With Higher
Difference Between Arms in Change p Value
ave velocity 0.167 (0.402 to 0.069) 0.164
27 0.471 (0.834 to 0.107) 0.014
70 0.031 (0.271 to 0.332) 0.839
1.190 (3.050 to 0.670) 0.207
31 2.647 (0.278 to 5.016) 0.030
82 2.825 (5.223 to 0.426) 0.022
beats/min 0.112 (1.833 to 2.058) 0.909
1.113 (5.458 to 3.232) 0.612
0.039 (0.221 to 0.299) 0.769
ivator* 0.036 (0.123 to 0.052) 0.425
bitor-1* 0.007 (0.131 to 0.116) 0.906
2.158 (4.789 to 0.472) 0.107
e 1.126 (2.624 to 0.372) 0.139
cient (95% CI). Change in parameters adjusted for baseline of the outcome, baseline
s), sex (male, female), and smoking pack-years (#20 pack-years, >20 pack-years).
; CRP ¼ C-reactive protein; LDL ¼ low-density lipoprotein.TC. Further investigation is required to understand
the impact of nicotine itself on longer term vascular
function.
In addition to these ﬁndings, we found a reduction
in resting heart rate in the >20 pack-years cohort who
switched to EC. The association between resting heart
rate and CV events is well known (26,27) and the link
between smoking cessation and reduction in heart
rate has been previously demonstrated in other
studies (28). However, this present study suggests
that a switch from TC to EC might also achieve this
early on in chronic smokers. A reduction in resting
heart rate as seen in this cohort of high CV risk,
chronic, heavy smokers would yield the greatest
beneﬁt, further supporting the beneﬁts of these co-
horts switching from TC to EC. Whether this might be
a transient phenomenon or translates to more sus-
tained beneﬁts requires further investigation.
We stress that whereas this study provides new
evidence for the rapid improvement of vascular
function when switching from TC to EC and there-
fore suggests that from a vascular perspective, EC
may be a less harmful alternative to TC, there is no
justiﬁcation nor evidence from our work to state
that EC are safe per se and therefore should
never be viewed by nonsmokers as harmless devices
to try.
COMPARISON WITH OTHER STUDIES. The vascular
impact of EC is a new and evolving ﬁeld and as such
there remains a signiﬁcant paucity of research in this
area. Carnevale et al. (29) reported a small (n ¼ 40)
single-use crossover study that demonstrated that
although both TC and EC had unfavorable effects on
markers of oxidative stress and FMD, EC had a lesser
impact than TC did. This result of our present study is
consistent with this ﬁnding. Hajek et al. (16) recently
reported that EC was more effective for smoking
cessation than nicotine replacement therapy was
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Smoking to-
bacco cigarettes is known to be harmful. In theory, EC contain
fewer harmful substances, but the health risks of EC are currently
not fully known.
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Patients who wish to stop smoking TC should be
offered less harmful options including switching to EC.
TRANSLATIONAL OUTLOOK: This study demonstrates the
early vascular impact of switching from TC to EC. Therefore,
switching to EC may be considered a vascular harms reduction
measure.
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3119when both products were accompanied by behav-
ioral support.
STUDY LIMITATIONS. This was a single-center study.
We could not perform a full 3-arm randomized
controlled design as it was unethical for participants
who wished to quit smoking to be allocated to the
smoking arm. We created a propensity score as an
adjustment covariate in the regressionmodels to allow
for any potential bias and the results remained
consistent. Baseline characteristics of the cohorts were
also comparable. The duration of effect tested was
deliberately short as the primary purpose of the study
was to investigate whether there were early vascular
beneﬁts from switching from TC to EC and the results
are reassuring. However, longer follow-up is required
to determine whether males also beneﬁt to the same
level as females do andwhether these changes seen are
sustained and to assess the impact of nicotine in EC.
There are many different EC devices available in the
market, and we tested only 1 device for consistency of
effect. Future comparative studies among different
devices are required. Finally, we used endothelial
dysfunction as an early indicator of CV disease and a
surrogate for CV events. However, endothelial
dysfunction has consistently been shown to correlate
well with longer term CV outcomes (12,13,30).
CONCLUSIONS
Smokers, particularly females, who switch from TC to
EC derive signiﬁcant beneﬁts in terms of vascularhealth, and this improvement is seen early on. From a
vascular health perspective, recommendations of
switching from TC to EC could be considered a
vascular harms reduction measure. Further investi-
gation is required on the long-term CV and non-CV
effects of these devices.
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